Cargando…

The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro

BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especia...

Descripción completa

Detalles Bibliográficos
Autores principales: Konishi, Misako, Ishizaki, Hiroshi, Kameyama, Ken-ichiro, Murakami, Kenji, Yamamoto, Takehisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311012/
https://www.ncbi.nlm.nih.gov/pubmed/30594182
http://dx.doi.org/10.1186/s12917-018-1724-5
_version_ 1783383534911619072
author Konishi, Misako
Ishizaki, Hiroshi
Kameyama, Ken-ichiro
Murakami, Kenji
Yamamoto, Takehisa
author_facet Konishi, Misako
Ishizaki, Hiroshi
Kameyama, Ken-ichiro
Murakami, Kenji
Yamamoto, Takehisa
author_sort Konishi, Misako
collection PubMed
description BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especially in young calves. In this study, to evaluate the protective ability of colostral antibodies against BLV infection, as well as the potential for BLV infection mediated by colostrum/milk, we investigated temporal fluctuations in the anti-BLV antibody titer and BLV proviral load (PVL) in colostrum/milk and peripheral blood of six infected dams during lactation. The association between PVL and antibody titer in colostrum and peripheral blood was then investigated using samples from a further twenty-seven cattle. Antibody concentrations were measured with a Syncytium-induction Inhibition Assay using colostral/milk whey and serum. PVL in peripheral blood and colostrum was measured by real-time PCR. RESULTS: Colostral antibodies showed high inhibitory activity until day 3 of lactation. The antibody titer and PVL in peripheral blood showed lesser changes than those in colostrum/milk throughout lactation. The colostral antibody titer was significantly higher than the serum antibody titer in all samples, whereas the colostrum PVL was significantly lower than the blood PVL. The blood PVL showed a significant correlation with serum antibody titer, colostrum PVL, and colostral antibody titer. However, there were no major correlations between the serum and colostral antibody titers. CONCLUSIONS: This is the first report investigating the temporal changes in colostral antibody titer in terms of inhibiting BLV infection in vitro. The results of antibody detection by Syncytium-induction Inhibition Assay suggested that the protective activity of the colostral antibodies against BLV infection would be conferred by anti-BLV gp51 antibody. The high antibody titer of colostral whey suggests that colostral whey could be a potential source of antibodies with a low risk of infection in neonatal calves.
format Online
Article
Text
id pubmed-6311012
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63110122019-01-07 The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro Konishi, Misako Ishizaki, Hiroshi Kameyama, Ken-ichiro Murakami, Kenji Yamamoto, Takehisa BMC Vet Res Research Article BACKGROUND: Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL). The incidence of EBL in Japan is increasing annually; and the cases of EBL in cattle younger than 2 years old has been reported. Therefore, it is vital to find a method to control BLV infection, especially in young calves. In this study, to evaluate the protective ability of colostral antibodies against BLV infection, as well as the potential for BLV infection mediated by colostrum/milk, we investigated temporal fluctuations in the anti-BLV antibody titer and BLV proviral load (PVL) in colostrum/milk and peripheral blood of six infected dams during lactation. The association between PVL and antibody titer in colostrum and peripheral blood was then investigated using samples from a further twenty-seven cattle. Antibody concentrations were measured with a Syncytium-induction Inhibition Assay using colostral/milk whey and serum. PVL in peripheral blood and colostrum was measured by real-time PCR. RESULTS: Colostral antibodies showed high inhibitory activity until day 3 of lactation. The antibody titer and PVL in peripheral blood showed lesser changes than those in colostrum/milk throughout lactation. The colostral antibody titer was significantly higher than the serum antibody titer in all samples, whereas the colostrum PVL was significantly lower than the blood PVL. The blood PVL showed a significant correlation with serum antibody titer, colostrum PVL, and colostral antibody titer. However, there were no major correlations between the serum and colostral antibody titers. CONCLUSIONS: This is the first report investigating the temporal changes in colostral antibody titer in terms of inhibiting BLV infection in vitro. The results of antibody detection by Syncytium-induction Inhibition Assay suggested that the protective activity of the colostral antibodies against BLV infection would be conferred by anti-BLV gp51 antibody. The high antibody titer of colostral whey suggests that colostral whey could be a potential source of antibodies with a low risk of infection in neonatal calves. BioMed Central 2018-12-29 /pmc/articles/PMC6311012/ /pubmed/30594182 http://dx.doi.org/10.1186/s12917-018-1724-5 Text en © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Konishi, Misako
Ishizaki, Hiroshi
Kameyama, Ken-ichiro
Murakami, Kenji
Yamamoto, Takehisa
The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title_full The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title_fullStr The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title_full_unstemmed The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title_short The effectiveness of colostral antibodies for preventing bovine leukemia virus (BLV) infection in vitro
title_sort effectiveness of colostral antibodies for preventing bovine leukemia virus (blv) infection in vitro
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311012/
https://www.ncbi.nlm.nih.gov/pubmed/30594182
http://dx.doi.org/10.1186/s12917-018-1724-5
work_keys_str_mv AT konishimisako theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT ishizakihiroshi theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT kameyamakenichiro theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT murakamikenji theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT yamamototakehisa theeffectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT konishimisako effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT ishizakihiroshi effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT kameyamakenichiro effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT murakamikenji effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro
AT yamamototakehisa effectivenessofcolostralantibodiesforpreventingbovineleukemiavirusblvinfectioninvitro